Strs Ohio Acquires Shares of 26,800 Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Strs Ohio purchased 26,800 shares of Kiniksa Pharmaceuticals valued at approximately $595,000 during the first quarter, reflecting significant institutional interest in the company.
• Insider trading activity included sales by COO Eben Tessari and CAO Michael R. Megna, with declines of 32.19% and 22.44% in their respective positions.
• Analysts are optimistic about Kiniksa Pharmaceuticals, with several price target increases, and an average rating of "Buy" with a price target of around $41.17.

Strs Ohio purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 26,800 shares of the company's stock, valued at approximately $595,000.

Several other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the period. US Bancorp DE acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $33,000. Asset Management One Co. Ltd. acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $41,000. Wealthquest Corp acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $42,000. Finally, Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $61,000. 53.95% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, insider Ross Moat sold 3,523 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total value of $124,397.13. Following the transaction, the insider directly owned 9,415 shares of the company's stock, valued at $332,443.65. This trade represents a 27.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $36.46, for a total transaction of $597,944.00. Following the sale, the chief operating officer directly owned 34,552 shares in the company, valued at approximately $1,259,765.92. The trade was a 32.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 561,371 shares of company stock valued at $18,825,009 over the last quarter. Insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Trading Up 0.3%

Shares of KNSA traded up $0.10 during midday trading on Tuesday, hitting $36.18. 87,247 shares of the company's stock traded hands, compared to its average volume of 652,092. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $37.34. The firm's fifty day moving average is $32.77 and its 200-day moving average is $27.80. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of 904.73 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on KNSA. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wells Fargo & Company increased their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.